A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2012
At a glance
- Drugs Carboplatin; Paclitaxel; Pazopanib
- Indications Gynaecological cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 12 May 2012 Planned number of patients changed from 46 to 52 as reported by European Clinical Trials Database record.
- 09 Oct 2009 Planned patient number (46) added as reported by ClinicalTrials.gov.